Omnitrope is a lab-made version of human growth hormone, given as a daily injection to treat growth failure in children and growth hormone deficiency in adults. It is FDA-approved for five specific pediatric conditions and one adult indication, making it one of the more broadly approved growth hormone products available.
Pediatric Uses
Omnitrope is approved to treat children whose growth is falling significantly behind for any of these reasons:
- Growth hormone deficiency (GHD): The child’s pituitary gland does not produce enough growth hormone on its own, leading to slower-than-expected growth.
- Prader-Willi syndrome: A genetic condition that causes poor muscle tone, short stature, and other developmental challenges. Diagnosis must be confirmed through genetic testing before treatment begins.
- Small for gestational age (SGA): Children who were born significantly smaller than expected and have not caught up to a normal growth pattern by age 2.
- Turner syndrome: A chromosomal condition affecting girls that typically results in short stature along with other health concerns.
- Idiopathic short stature (ISS): Children who are very short (height at or below the 1.2nd percentile for their age) without a clear medical explanation, and whose growth rate makes it unlikely they will reach a normal adult height. The child’s growth plates must still be open, meaning they still have the biological ability to grow taller.
In each of these cases, the goal is the same: to restore or accelerate growth velocity so the child reaches a more typical adult height. Treatment usually begins once the diagnosis is confirmed and continues until the child reaches an acceptable height or their growth plates close, whichever comes first.
Adult Uses
In adults, Omnitrope is approved for growth hormone deficiency, which can develop either as a continuation of childhood GHD or as a new problem caused by damage to the pituitary gland. Pituitary tumors, surgery, radiation therapy, or traumatic brain injury are common causes.
Diagnosing adult GHD is more involved than a simple blood draw. Growth hormone is released in pulses throughout the day, so a single measurement of blood levels is unreliable. Instead, doctors typically use a stimulation test: a substance is given to trigger growth hormone release, and blood is drawn at timed intervals to see how the pituitary responds. In some cases, if a patient already has multiple pituitary hormone deficiencies and low levels of a marker called IGF-1, the stimulation test can be skipped.
Adults with untreated growth hormone deficiency often experience reduced muscle mass, increased body fat (especially around the midsection), low bone density, fatigue, and a higher cardiovascular risk profile. Treatment with Omnitrope aims to reverse or improve these changes. Patients report increased energy and motivation, reduced fatigue, better mood and mental clarity, and improved body composition over time.
How Omnitrope Is Given
Omnitrope is injected just under the skin, typically once daily. Most patients use a prefilled pen device that makes the process similar to using an insulin pen. Injection sites are rotated between the thighs, abdomen, buttocks, and upper arms to prevent skin irritation or tissue changes at any one spot.
For children, a parent or caregiver usually handles injections until the child is old enough and comfortable enough to self-inject. Many families settle into an evening routine, since the body naturally releases most of its growth hormone during sleep. The injection itself uses a small needle and takes only a few seconds.
What Monitoring Looks Like During Treatment
Growth hormone therapy is not a “set it and forget it” treatment. Regular bloodwork is a standard part of the process, both to make sure the dose is working and to catch potential side effects early.
IGF-1, a protein that rises and falls with growth hormone activity, is the primary marker used to track how well treatment is working. During the initial dose-adjustment phase for adults, blood is typically rechecked every one to two months. Once a stable maintenance dose is reached, testing moves to every six to twelve months.
Because growth hormone affects metabolism broadly, doctors also monitor thyroid function, since treatment can lower free thyroid hormone levels. Fasting cholesterol and lipid panels are checked every six to twelve months due to the cardiovascular risks associated with GHD. For patients at higher risk of diabetes, blood sugar and hemoglobin A1c may be tracked as well. In children, height, weight, and growth velocity are measured at regular clinic visits to confirm that the treatment is producing meaningful gains.
Common Side Effects
Most side effects of Omnitrope are related to the body adjusting to higher growth hormone levels. Joint pain, muscle pain, and swelling in the hands or feet from fluid retention are among the most frequently reported issues in adults. These tend to be dose-related, meaning they often improve when the dose is lowered.
In children, injection-site reactions like redness or mild pain are common, especially early in treatment. Headaches can also occur. More serious but less common concerns include increased pressure inside the skull (which can cause persistent headaches and vision changes), changes in blood sugar levels, and the possibility of a curvature of the spine worsening in children with rapid growth.
For children with Prader-Willi syndrome, there is a specific safety concern: cases of serious breathing problems have been reported, particularly in children who are severely overweight or have existing respiratory issues. This is why close medical supervision is especially important in this group.
Who Should Not Use Omnitrope
Omnitrope is not appropriate for everyone. It should not be used by anyone with an active cancer or tumor, since growth hormone can promote cell growth. It is also not used in critically ill patients recovering from major surgery, serious injuries, or acute respiratory failure. Children whose growth plates have already closed will not benefit, because the biological window for height gain has passed. Anyone with a known allergy to growth hormone or any ingredient in the formulation should avoid it as well.